Sturgeon CM, Sprague S, Almond A, Cavalier E, Fraser WD, Algeciras-Schimnich A, et al. IFCC Working Group for PTH. Perspective and priorities for improvement of parathyroid hormone (PTH) measurement – a view from the IFCC Working Group for PTH. Clin Chim Acta 2017;467:42–7.Web of ScienceCrossrefGoogle Scholar
Hecking M, Kainz A, Bielesz B, Plischke M, Beilhack G, Hörl WH, et al. Clinical evaluation of two novel biointact PTH(1-84) assays in hemodialysis patients. Clin Biochem 2012;45:1645–51.CrossrefWeb of SciencePubMedGoogle Scholar
Gannagé-Yared MH, Farès C, Ibrahim T, Rahal ZA, Elias M, Chelala D. Comparison between a second and a third generation parathyroid hormone assay in hemodialysis patients. Metabolism 2013;62:1416–22.CrossrefWeb of ScienceGoogle Scholar
O’Flaherty D, Sankaralingam A, Scully P, Manghat P, Goldsmith D, Hampson G. The relationship between intact PTH and biointact PTH (1-84) with bone and mineral metabolism in pre-dialysis chronic kidney disease (CKD). Clin Biochem 2013;46:1405–9.CrossrefPubMedWeb of ScienceGoogle Scholar
Tan K, Ong L, Sethi SK, Saw S. Comparison of the Elecsys PTH(1-84) assay with four contemporary second generation intact PTH assays and association with other biomarkers in chronic kidney disease patients. Clin Biochem 2013;46:781–6.PubMedWeb of ScienceCrossrefGoogle Scholar
Cavalier E, Betea D, Schleck ML, Gadisseur R, Vroonen L, Delanaye P, et al. The third/second generation PTH assay ratio as a marker for parathyroid carcinoma: evaluation using an automated platform. J Clin Endocrinol Metab 2014;99:E453–7.PubMedWeb of ScienceCrossrefGoogle Scholar
Cavalier E, Delanaye P, Lukas P, Carlisi A, Gadisseur R, Souberbielle JC. Standardization of DiaSorin and Roche automated third generation PTH assays with an International Standard: impact on clinical populations. Clin Chem Lab Med 2014;52:1137–41.Web of SciencePubMedGoogle Scholar
Bonanséa TC, Ohe MN, Brandão C, Ferrer CF, Santos LM, Lazaretti-Castro M, et al. Experience with a third-generation parathyroid hormone assay (BIO-PTH) in the diagnosis of primary hyperparathyroidism in a Brazilian population. Arch Endocrinol Metab 2016;60:420–5.CrossrefWeb of ScienceGoogle Scholar
Einbinder Y, Benchetrit S, Golan E, Zitman-Gal T. Comparison of intact PTH and bio-intact PTH assays among non-dialysis dependent chronic kidney disease patients. Ann Lab Med 2017;37:381–7.CrossrefPubMedWeb of ScienceGoogle Scholar
Cavalier E, Salsé M, Dupuy AM, Bargnoux AS, Watar F, Souberbielle JC, et al. Establishment of reference values in a healthy population and interpretation of serum PTH concentrations in hemodialyzed patients according to the KDIGO Guidelines using the Lumipulse® G whole PTH (3rd generation) assay. Clin Biochem 2018;54:119–22.CrossrefWeb of ScienceGoogle Scholar
London G, Coyne D, Hruska K, Malluche HH, Martin KJ. The new kidney disease: improving global outcomes (KDIGO) guidelines – expert clinical focus on bone and vascular calcification. Clin Nephrol 2010;74:423–32.Web of ScienceGoogle Scholar
Moe SM, Drüeke TB, Block GA, Cannata-Andía JB, Elder GJ, Fukagawa M, et al. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of chronic kidney disease mineral and bone disorder (CKD-MBD). Kidney Int 2009;76:S1–28.Google Scholar
KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney International Supplements 2017;7:1–59.Google Scholar
Gardham C, Stevens PE, Delaney MP, LeRoux M, Coleman A, Lamb EJ. Variability of parathyroid hormone and other markers of bone mineral metabolism in patients receiving hemodialysis. Clin J Am Soc Nephrol 2010;5:1261–7.CrossrefPubMedWeb of ScienceGoogle Scholar
About the article
Published Online: 2018-09-05
Published in Print: 2018-12-19
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.